GSK: DREAMM-3 trial failed to meet primary endpoint of progression-free survival (PFS)
ADC评论
November 8, 2022
On November 7, GSK announced that the Phase III open-label, randomized, head-to-head superiority DREAMM-3 trial failed to meet the primary endpoint of progression-free survival (PFS).
